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Abstract
Background Neuroleptic malignant syndrome (NMS) is a
rare, severe, idiosyncratic adverse reaction to antipsychot-
ics. Second-generation antipsychotics (SGAs) were origi-
nally assumed to be free from the risk of causing NMS,
however several cases of NMS induced by SGAs (SGA-
NMS) have been reported.
Objectives The aim of this study was to systematically
review available studies and case reports on SGA-NMS
and compare the presentation of NMS induced by different
SGAs.
Data Sources Citations were retrieved from PubMed up
to November 2013, and from reference lists of relevant
citations.
Study Eligibility Criteria Eligibility criteria included
(a) primary studies reporting data on NMS, with at least
50 % of the sample receiving SGAs; or (b) case reports
and case reviews reporting on NMS induced by SGA
monotherapy, excluding those due to antipsychotic
withdrawal.
Study Appraisal and Synthesis Methods A standardized
method for data extraction and coding was developed for
the analysis of eligible case reports.
Results Six primary studies and 186 individual cases
of NMS induced by SGAs were included. Primary
studies suggest that SGA-NMS is characterized by
lower incidence, lower clinical severity, and less fre-
quent lethal outcome than NMS induced by first-gen-
eration antipsychotics. Systematic analysis of case
reports suggests that even the most recently marketed
antipsychotics are not free from the risk of inducing
NMS. Furthermore, clozapine-, aripiprazole- and ami-
sulpride-induced NMS can present with atypical fea-
tures more frequently than other SGA-NMS, i.e.
displaying less intense extrapyramidal symptoms or
high fever.
Limitations Case reports report non-systematic data,
therefore analyses may be subject to bias.
Conclusions and Implications of Key Findings Clinicians
should be aware that NMS is virtually associated with all
antipsychotics, including those most recently marketed.
Although apparently less severe than NMS induced by
older antipsychotics, SGA-NMS still represent a relevant
clinical issue.
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Key Points
Neuroleptic malignant syndrome (NMS) induced by
second-generation antipsychotics is characterized by
lower incidence, lower clinical severity, and less
frequent lethal outcome than NMS induced by first-
generation antipsychotics.
Even the most recently marketed antipsychotics are
not free from the risk of inducing NMS.
Clozapine-, aripiprazole- and amisulpride-induced
NMS can present with atypical features more
frequently than other SGA-NMS, i.e. displaying less
intense extrapyramidal symptoms or high fever.
1 Introduction
Neuroleptic malignant syndrome (NMS) is a rare, unpre-
dictable adverse reaction associated with antipsychotic use.
It is generally characterized by rigidity, tremor, fever,
dysregulated sympathetic nervous system hyperactivity,
alterations of mental status, leukocytosis, and creatine
kinase (CK) elevation [1]. If not promptly recognized and
treated, NMS can lead to patient death or permanent
damages, such as neurological sequelae [2, 3]. Second-
generation antipsychotics (SGAs) were initially assumed to
be free from the risk of inducing NMS because of their
more favorable pharmacodynamic profile [4]; however,
after they had been marketed, cases of NMS induced by
SGAs (SGA-NMS) began to be reported, with the first case
implicating clozapine [5]. Notably, several cases of NMS
induced by clozapine (CLZ-NMS) presented with different
clinical features than those of NMS induced by first-gen-
eration antipsychotics (FGA-NMS), i.e. lacking cardinal
signs or symptoms. These observations led to the hypoth-
esis that ‘atypical’ antipsychotics might determine ‘atypi-
cal’ forms of NMS on the basis of different
pharmacological properties [6]. Furthermore, newer SGAs
such as aripiprazole [7] and amisulpride [8] possess
peculiar pharmacodynamic profiles [9, 10] which might be
associated with different NMS presentation. At present,
while it is commonly accepted that no antipsychotic is free
from the risk of inducing NMS, there is still uncertainty on
the clinical profile of SGA-NMS [6, 11].
SGAs are the most commonly prescribed antipsychotics
[12] but our knowledge on SGA-NMS continues to be very
limited given the intrinsic difficulties of studying NMS
under experimental conditions. Of note, case reports
remain one of the main sources of information for clini-
cians. Hence, there is still great uncertainty regarding
SGA-NMS epidemiology [13, 14], diagnostic definition
[1], presentation, clinical course, and pathophysiology [15],
and possible influence of concomitant drugs [16]. Consid-
erable time has elapsed since this topic was examined in a
systematic fashion [6], hence our aim was to review the
available evidence on SGA-NMS, considering both pri-
mary studies and case reports. In order to minimize the risk
of bias in the interpretation of available evidence, a stan-




The Pubmed database was searched using the following
search string: \Malignant AND (‘Antipsychotic Agents’
[Mesh] OR amisulpride OR aripiprazole OR asenapine OR
clozapine OR olanzapine OR paliperidone OR quetiapine
OR risperidone OR ziprasidone OR iloperidone OR zote-
pine OR sertindole OR lurasidone)[. Two independent
researchers screened and systematically assessed all
retrieved references to identify (1) primary studies on
SGA-NMS, i.e. those conducted on clinical samples; and
(3) case reports or case reviews of SGA-NMS. All works
published prior to November 2013 as well as relevant
citations obtained from bibliographies were screened. In
addition to citations in English, those written in Italian,
Spanish, and French were included as two researchers were
fluent in these languages.
2.2 Inclusion and Exclusion Criteria
For the review of primary studies, any study that reported
data on NMS developed during a treatment course with any
SGA was included. If studies were conducted on samples
where NMS was developed during treatment with both
FGAs and SGAs, only those where at least 50 % of par-
ticipants were treated with SGAs were included.
For the review of case reports, the aim was to obtain the
maximum degree of clinical homogeneity; hence, cases
(a) with an unclear diagnosis of NMS, meaning that the
reporting clinician did not explicitly state this diagnosis,
irrespective of the set of diagnostic criteria that were used
[1]; (b) where an SGA was given in association with
another antipsychotic (either FGA or SGA) in the week
preceding the diagnosis of NMS; and (c) where the NMS
was apparently induced by withdrawal of an antipsychotic
[15, 17], were excluded.
46 M. Belvederi Murri et al.
2.3 Data Extraction
For the case review, researchers extracted, coded, and
analyzed relevant data available from case reports using a
standardized method (described in detail in the Methods
section of the Online Resource). Briefly, two researchers
(AG and MB), blinded to each other, coded for each case
detailed information on subject sociodemographic and
clinical features, treatment with SGAs and other psycho-
tropic drugs, NMS clinical presentation, course and man-
agement. In order to provide a description of the time
course of NMS, all available data relative to the temporal
sequence of events were extracted. An adapted version of
the Francis–Yacoub NMS Rating Scale [18] was used to
improve the homogeneity for the ratings of NMS severity.
2.4 Statistical Analysis
For all cases of SGA-NMS, a summary of descriptive data
was reported, including demographic and clinical character-
istics. Furthermore, to explore the presence of potential
intraclass differences between cases of NMS prompted by
different SGAs, exploratory statistical analyses were con-
ducted comparing the demographic and clinical characteris-
tics of cases by means of the Chi-square test and analysis of
variance (ANOVA). Since description of the case reports was
not conducted in a systematic fashion, a significant amount of
missing data was expected; to provide the reader with an
estimation of the representativity of results, the percentage of
cases with missing data for each comparison is reported.
Also, Pearson’s correlation index (R) and Student’s t test
were used to test whether sociodemographic and clinical
features of NMS showed associations with the global severity
of NMS (expressed as the total severity score for each case).
Statistical analyses were conducted including only the SGA-
NMS groups where a sufficient number of NMS cases were
available (setting an arbitrary threshold of ten cases per
subgroup), using the Statistical Package for Social Sciences,
version 15.0 (SPSS Inc., Chicago, IL, USA).
3 Results
3.1 Search Results
The search yielded 918 citations (see Fig. S1 in the Online
Resource). Of these, six primary studies were included in
the review [11, 14, 19–22], while 247 case reports were
potentially eligible for inclusion. After full-text review,
105 more citations were excluded, leading to the inclusion
of 142 citations (case reports or case series). These
accounted for 186 individual case reports of SGA-NMS.
References for included case reports are included in the
References section of the Online Resource. Table 1 reports
the description of the included primary studies.
3.2 Case Report Analysis
Tables 2, 3 and 4 report data on cases of SGA-NMS that
were considered for statistical analysis (n = 155): 42 cases
of NMS were induced by olanzapine (OLA, mean dose
12 ± 5.8 mg), 44 by risperidone (RSP, mean dose
3.7 ± 3.2 mg), 19 by quetiapine (QUE, 335 ± 270 mg),
36 by clozapine (CLZ, 332 ± 263 mg), and 14 by aripip-
razole (ARP, 18.9 ± 9.2 mg). Table 5 reports descriptive
data of those cases of SGA-NMS for which only descrip-
tive analyses are provided. These were induced by ami-
sulpride (AMI, n = 7; mean dose 480 ± 179 mg),
ziprasidone (ZPR, n = 6; 86.7 ± 46.8 mg), paliperidone
(PAL, n = 4; 7.5 ± 1.7 mg), and zotepine (ZOT, n = 4;
325 ± 247 mg). Lastly, because of a low number of cases,
ten cases of NMS induced by other antipsychotics (pero-
spirone, clotiapine, tiapride, iloperidone, asenapine, rem-
oxipride) were excluded from the review.
The majority of case reports did not specify which
diagnostic criteria set was used for the diagnosis of NMS
(n = 131, 70.1 %), whereas in the remainder of cases the
Diagnostic and Statistical Manual of Mental Disorders, 4th
edition, text revision (DSM-IV-TR) criteria were used most
commonly (n = 35,18.7 %) [23], followed by the criteria
of Levenson (n = 13, 7 %) [24], Sachdev (n = 3, 1.6 %)
[25], Pope et al. (n = 2, 1.1 %) [26], and Caroff and Mann
(n = 2, 1.1 %) [27].
3.3 Intraclass Comparison of Cases of Second-
Generation Antipsychotic-Induced Neuroleptic
Malignant Syndrome (SGA-NMS)
3.3.1 Sociodemographic, Clinical Features and Treatment
with SGAs
Table 1 reports the comparison of subjects’ sociodemo-
graphic and clinical features by each SGA-NMS. In the
overall sample, the mean age was 41.5 ± 20.2. The
majority were males (62.6 %), and the diagnoses were
psychotic disorders (58.3 %), mood disorders (23.2 %),
dementia (9.3 %), or other disorders (9.3 %). Half of the
subjects receiving CLZ (50 %) and one-third of those
treated with olanzapine (34.8 %) had already suffered from
NMS in the past, whereas none of the subjects in the ari-
piprazole group (p = 0.04) had developed NMS.
Among those patients receiving risperidone and aripip-
razole, more were antipsychotic-naı¨ve than in the clozapine
subgroup (41.2 and 38.5 vs. 4.0 %; p = 0.01). The mean
reported doses of SGAs on the day of NMS insurgence
were very similar between the five subgroups (p = 0.89).





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































50 M. Belvederi Murri et al.
Instead, a steep dose titration before NMS was found more
frequently in the aripiprazole group than in the quetiapine
group (50 vs. 10.5 %; p = 0.04). Olanzapine, quetiapine,
and risperidone were more often associated with antide-
pressant use than clozapine and aripiprazole. Lithium was
prescribed to 5.3 % of participants using quetiapine and up
to 13.9 % of those taking clozapine.
3.3.2 NMS Clinical Features
The comparisons of the prevalence, duration, and
severity of NMS symptoms are reported in Table 3. The
clinical presentation of NMS showed significant differ-
ences according to the SGA used; rigidity and tremor
were less frequent in CLZ-NMS than in other subgroups
(p \ 0.01 and p = 0.03, respectively). While a degree of
hyperpyrexia was almost ubiquitary, higher temperatures
were less commonly observed for aripiprazole (58.3 %)
than other SGAs, but this difference did not reach sta-
tistical significance (p = 0.10). Diaphoresis was constant
or very frequent in olanzapine, quetiapine, and clozapine
(100, 100, and 94 %, respectively), less frequent in
risperidone (75 %), and in cases of aripiprazole-induced
NMS (ARP-NMS) [42.9 %; p = 0.001]. Considering
laboratory tests, both CK elevation and leukocyto-
sis were very frequent without showing intra-class
differences.
Global severity was significantly lower for CLZ–NMS
than risperidone-induced NMS (RSP-NMS) [p = 0.02] or
olanzapine-induced NMS (OLA-NMS) [p = 0.03]. There
was no significant association between global severity and
age (r = 0.07, p = 0.48), gender (t = 1.37, p = 0.17),
diagnoses (F = 0.18, p = 0.91), antipsychotic dose
(r = 0.08, p = 0.44) or percentage of dose increase in the
preceding week (r = 0.13, p = 0.48), use of mood stabi-
lizers (t = 0.49, p = 0.69) or benzodiazepines (t = 0.76,
p = 0.45) in the preceding week. There was a statistical
trend for an association between antidepressant use in the
past week and a higher global severity (37.0 ± 9.6 vs.
32.4 ± 8.7; p = 0.08) but this disappeared after adjusting
for the type of antipsychotic.
There were differences in the timing of the onset of
some symptoms between the SGA-NMS subgroups (see
Table 5), although no comparison reached statistical














Gender [female; %] 33.3 42.1 50 42.9 22.2 – v2 = 7.18, df = 4, p = 0.13
Age [years; mean ± SD] 46.2 ± 22.4 45.3 ± 18.8 39.6 ± 21.2 32.1 ± 18.2 39.9 ± 16.3 – F = 1.68, df = 4, p = 0.16
Ethnicity [Caucasian; %] 41.2 42.9 55 60 87.5 93 (60) v2 = 9.74, df = 12, p = 0.64c
Diagnosis [%] 4 (2.6) v2 = 13.99, df = 12, p = 0.3
Psychotic disorders 52.5 44.4 50 71.4 77.1
Mood disorders 25 27.8 25 21.4 17.1
Dementia 15 15 9.1 – 2.9
Other 7.5 7.5 15.9 7.1 2.9
Previous NMS [%] 34.8 12.5 12.5 0 50 119 (76) v2 = 9.74, df = 4, p = 0.04*c
AP naive [%] 26.7 15.4 41.2 38.5 4.0 40 (26) v2 = 12.15, df = 4, p = 0.02*,c
Dose [mg; mean ± SD] 12.1 ± 5.9 335 ± 270 3.7 ± 3.2 18.9 ± 9.2 332 ± 263 23 (15) –
CPZ eq [mean ± SD] 253 ± 124 236 ± 190 279 ± 240 295 ± 144 308 ± 243 23 (15) F = 0.48, df = 4, p = 0.75
Dose increase [%]a 33.3 15.8 25 50 36.1 – v2 = 5.71, df = 4, p = 0.22
Dose increase C50 [%]b 30.0 10.5 25 50 33.3 – v2 = 6.87, df = 4, p = 0.14
Other treatments [%]
SSRI 11.9 10.5 11.4 7.1 2.8 31 (20) v2 = 2.54, df = 4, p = 0.64
Other AD 4.8 5.3 6.8 0 2.8 31 (20) v2 = 1.49, df = 4, p = 0.83
LIT 11.9 5.3 13.6 7.1 13.9 31 (20) v2 = 1.38, df = 4, p = 0.85
Other MS 21.4 10.5 13.6 7.1 8.3 31 (20) v2 = 3.7, df = 4, p = 0.45
AD antidepressant, AP antipsychotic, ARP aripiprazole, CLZ clozapine, CPZ eq chlorpromazine equivalents, df degrees of freedom, LIT lithium,
NMS neuroleptic malignant syndrome, OLA olanzapine, QUE quetiapine, RSP risperidone, SSRI selective serotonin reuptake inhibitor, MS mood
stabilizers, SD standard deviation
* p \ 0.05
a Any dose increase of AP in the 5 days preceding NMS onset
b Percentage of dose increase was calculated as 100 % when the APs were newly introduced in the 5 days before NMS diagnosis
c Missing values over 25 %




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































52 M. Belvederi Murri et al.
significance. For olanzapine and clozapine, the first
symptoms to appear were autonomic disorders (nausea,
vomiting, and fecal and urinary incontinence), while for
risperidone and aripiprazole, the first symptoms to appear
were extrapyramidal symptoms (EPS; akathisia, diskinesia,
bradikinesia, myoclonus, hyperreflexia, hyporeflexia).
Quetiapine-induced NMS (QUE-NMS) seemed to appear
suddenly, showing most symptoms on the same day, with
the exception of diaphoresis and tremor. In most cases,
rigidity and tremor appeared rapidly, particularly in RSP-
NMS (mean 1.5 and 1.7 days before NMS diagnosis,
respectively), while in CLZ-NMS, hyperpyrexia and
tachycardia were early symptoms (2.2 and 1.4 days before
NMS diagnosis, respectively). Finally, CK elevation
always followed the NMS date, particularly in the aripip-
razole subgroup.
3.3.3 NMS Management and Clinical Outcomes
Table 4 reports the comparison of clinical management
between the subgroups of SGA-NMS. Only one-third of
patients required intubation and transfer to the intensive
care unit (ICU), with no intraclass differences. Antipar-
kinsonian drugs were used in approximately half of the
cases in the risperidone and aripiprazole subgroups, and in
one third of those in the olanzapine and clozapine groups
(p = 0.07).
Complete recovery was the most frequent outcome, with
highest rates in the risperidone groups (87.9 %) and the
lowest in the quetiapine groups (61.5 %; p = 0.37).
Overall, a fatal outcome was reported in less than 10 % of
cases—from no reported cases for aripiprazole to 7.1 % for
clozapine, and 7.7 % for those receiving quetiapine
(p = 0.81). Exploratory analyses showed that lethal cases
were older in age than non-lethal cases (59.5 ± 14 vs.
40.0 ± 20.5; t = 2.64; p = 0.009), while they did not
differ significantly in terms of gender (p = 0.47) or pre-
vious use of antipsychotic (p = 0.81). The dose of anti-
psychotic in chlorpromazine equivalents was even lower,
although not significantly (295 ± 209 vs. 141 ± 102;
t = 1.63; p = 0.11). Use of mood stabilizers was not
associated with death (p = 0.62), while the use of an
antidepressant in the preceding week showed a more fre-
quent trend in lethal cases than in non-lethal cases (37.5.
vs. 12.4 %; v2 = 4.00; p = 0.08), that persisted after
adjusting for age (p = 0.07).
4 Discussion
The aim of this review was to systematically examine the
available evidence on NMS induced by SGAs. Primary































































































































































































































































































































































































































































































Second-Generation Antipsychotics and NMS 53
regard to its epidemiology, clinical features, and outcomes.
Furthermore, the analysis of case reports of SGA-NMS
highlighted the presence of clinical heterogeneity among
NMS induced by different SGAs, particularly for cloza-
pine, aripiprazole, and amisulpride.
4.1 Comparison Between SGA-NMS and First-
Generation NMS
Almost 30 years have elapsed since Pope and colleagues
reported the first case of NMS induced by an atypical
antipsychotic [5]. Despite this, the knowledge on SGA-
NMS is still quite limited and few studies have been con-
ducted with a systematic methodology. Available evidence
suggests that NMS is less frequent during treatment with
SGAs than with FGAs. Two studies collected spontaneous
reporting from pharmacovigilance databases and estimated
an annual incidence of SGA-NMS at 0.056/(1,000 9 year)
in patients receiving olanzapine [14] and 0.064/
(1,000 9 year) among patients receiving various SGAs
[19], whereas a recent meta-analysis indicated that SMN
occurred in 0.17–32 persons for every 1,000 receiving
FGAs [13]. However, both figures relative to FGAs and
SGAs should be considered only indicative given that
epidemiological data on SMN are affected by significant
methodological bias. Furthermore, the meta-analysis
reporting data on FGA-NMS is more likely to have over-
estimated its prevalence since it included studies that were
mostly conducted on inpatients, among whom NMS tends
to occur more frequently. However, in a direct comparison,
SGAs were still associated with an almost threefold higher
probability of incident NMS than FGAs [22].
A few significant risk factors for SGA-NMS could be
identified, i.e. male gender, confusion, dehydration, delir-
ium, and EPS in one study [19], and non-White ethnicity,
number of antipsychotics, use of aripiprazole, and
increasing/fluctuant dosing patterns in another [22]. This is
broadly similar to findings on FGA-NMS, although data
are still too limited to draw meaningful comparisons [28,
29].
Only one study directly compared the clinical features of
SGA-NMS and FGA-NMS, and did not find overall
between-class differences. However, it is noteworthy that
CLZ-NMS alone was characterized by less rigidity and
EPS than other SGAs [11]. Other studies also suggested
that SGA-NMS was associated with a less severe clinical
picture than FGA-NMS, since the authors found lower
rates of admissions to the ICU [20], and lower mortality
rates than for FGA-NMS [11, 20]. In our case review, eight
cases of SGA-NMS were lethal, from a total of 145 cases
that reported this information (5.5 %). Therefore, the
mortality rate seems to be much lower for SGA-NMS than
previous estimates of 10–20 % among cases of FGA-NMS
[30, 31]. Consistent with other reports, in our analysis
lethal cases tended to occur in older individuals [11, 31].
4.2 NMS Induced by SGAs
Newer antipsychotics are commonly grouped under the
umbrella term of ‘atypical’ or ‘second-generation’ com-
pounds, given their relative freedom from risks of adverse
extrapyramidal effects [4, 11]. However, it was well
established that each SGA possesses specific pharmacoki-
netic and pharmacodynamic properties, as well as different
profiles of clinical effects and toxicity [9, 10]. Pharmaco-
logical properties might constitute the basis of intraclass
differences in the expression of SGA-NMS.
4.2.1 Olanzapine
Cardinal signs of NMS were present in the vast majority of
cases of OLA-NMS, while 10–20 % did not display EPS or















ICU and intubation 35.7 30.0 24.2 38.5 29.2 47 (30) v2 = 1.38, df = 4, p = 0.85a
Any antiparkinsonian 34.4 40 59.0 53.8 27.6 27 (17) v2 = 8.52, df = 4, p = 0.07
Dopaminergic 30.3 40 53.8 38.5 27.6 26 (17) v2 = 6.27, df = 4, p = 0.18
Anticholinergic 3.1 6.7 10.3 23.1 3.4 27 (17) v2 = 6.30, df = 4, p = 0.18
Myorelaxants 51.5 86.7 48.7 61.5 51.3 26 (17) v2 = 7.21, df = 4, p = 0.13
Outcome [%]
Complete recovery 75 61.5 87.9 81.8 80 50 (32) v2 = 4.32, df = 4, p = 0.37a
Death 6.5 7.7 2.9 0 7.1 36 (23) v2 = 1.64, df = 4, p = 0.81
ARP aripiprazole, CLZ clozapine, df degrees of freedom, ICU intensive care unit, NMS neuroleptic malignant syndrome, OLA olanzapine, QUE
quetiapine, RSP risperidone
a Missing values over 25 %
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high fever. On average, symptoms of autonomic imbal-
ances were only slightly more frequent in OLA-NMS than
in other SGA-NMS, but were often the first signs to appear
(up to 5 days prior to NMS diagnosis), followed by EPS
and mental status change, and then diaphoresis and fever.
Nausea was rare, consistent with established olanzapine
antiemetic properties [32], except when it was administered
together with sertraline [33] or valproate [34]. Among the
most peculiar clinical cases that were reported, OLA-NMS
displayed severe neurological symptoms, such as coma
[35], hemiplegia [36], ataxia [37], and seizures [38].
Overall, OLA-NMS was reported to be quite rare [14], but
several cases have been described in patients taking psy-
choactive drugs other than antipsychotics, such as antide-
pressants or mood stabilizers. In these cases, the resulting
clinical picture was often characterized by a higher global
severity, and resulted in substantial mortality rates. In
general, despite the fact that OLA-NMS might present with
a different clinical picture than those of typical FGA-NMS,
these findings do not seem sufficient to justify the defini-
tion of an atypical presentation, as was also noted by
previous authors [6, 39, 40].
4.2.2 Quetiapine
The average age of cases suffering from QUE-NMS was
high, although one case was reported in a 4-year-old
patient [41]. Clinically, QUE-NMS was characterized by
the constant presence of EPS and pronounced autonomic
symptoms, such as diaphoresis, tachycardia, tachypnea,
Table 5 Neuroleptic malignant syndrome induced by amisulpride, paliperidone, ziprasidone, and zotepine
AMI (n = 7) PAL (n = 4) ZPR (n = 6) ZOT (n = 4) Missing [n (%)]
Gender, female 28.6 50 66.7 25 –
Age [years; mean ± SD] 47.6 ± 18.9 39.5 ± 24.7 35 ± 16.1 52.5 ± 13.6 –
Ethnicity [Caucasian; %] 33.3 100 – 40 18 (60)
Diagnosis [%]
Psychotic disorders 42.9 75 66.7 100
Mood disorders 28.6 – 33.3 –
Dementia 28.6 – – –
Other – 25 – –
Mean dose [mean ± SD]a 480 ± 179 7.5 ± 1.7 86.7 ± 46.8 325 ± 247 8 (26.7)
Symptoms [%]
Mental status change 100 100 100 100 2 (6.7)
Rigidity 83.3 100 80 100 5 (16.7)
Diaphoresis 75 100 100 100 12 (38.7)
Hyperpyrexia 71.4 100 100 100 3 (10)
Temperature C38 C 50 50 50 66.7 4 (13.3)
Tachycardia 80 100 100 100 10 (33.3)
Tachypnea – – 33 – 24 (80)
BP alteration 83.3 75 83.3 – 7 (23.3)
Other autonomic symptoms 100 25 33.3 – –
Tremor – 100 100 50 17 (56.7)
Other EPS – 100 100 – 23 (76.7)
Laboratory tests
CK [100 UI/l; mean ± SD] 77.9 ± 62.9 74.2 ± 129 319 ± 437 21.3 ± 37.3 –
CK peak [100 UI/l; mean ± SD] 79.5 ± 61.5 76.7 ± 128 382 ± 475 392 ± 392 3 (10)
Leukocytosis [%] 80 50 80 100 10 (33.3)
WBC [1,000 U/l; mean ± SD] 16.6 ± 4.8 16.2 20 ± 9.4 15.3 ± 2.9 15 (50)
Symptom duration [days; mean ± SD] 10.5 ± 5.8 14.2 ± 5.7 10.4 ± 1.5 15.0 ± 1.5 12 (40)
Outcome [%]
Complete recovery 80 100 75 100 10 (33.3)
Death 20 – – – 7 (23.3)
AMI amisulpride, BP blood pressure, CK creatine kinase, EPS extrapyramidal symptoms, PAL paliperidone, SD standard deviation, WBC white
blood cells, ZPR ziprasidone, ZOT zotepine
a Mean dose on the day of NMS onset
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and blood pressure alterations. In particular, the latter
symptoms might be related to its inhibition of noradrena-
line reuptake, a-adrenergic and histaminergic antagonism,
and also to serotonin-related toxicity [10]. Of note, this
clinical picture was observed in spite of similar patterns in
the prescription of other psychotropic drugs, such as anti-
depressants or mood stabilizers. Symptoms of QUE-NMS
seemed to have their onset synchronously, on average a day
before the diagnosis of NMS was made. Furthermore,
QUE-NMS had the longest duration among SGA-NMS.
Together, these elements suggest that an abrupt onset
prompted an early diagnosis of NMS by the reporting cli-
nicians, thus prolonging the observation period. The mean
severity index was in the low range, but the observed
outcomes were overall poor, despite patients received
similar supportive treatments as in other SGA-NMS. This
is in apparent contrast with previous case reports [6, 42],
but might be explained by the higher age of the subjects,
which is a significant predictor of negative outcomes [11,
43]. In addition, symptoms of autonomic dysfunction were
given a smaller weight than other dimensions of NMS in
the rating of clinical severity [18], and this might have led
to a relative underestimation of the severity of QUE-NMS.
Overall, the clinical picture of QUE-NMS seems similar to
that of OLA-NMS, which is consistent with several com-
monalities in their pharmacological profiles [10]; this
suggests caution in the definition of an ‘atypical’
presentation.
4.2.3 Risperidone
Since publication of the review by Trollor and colleagues
[6], ten cases of RSP-NMS have been published. Overall,
RSP-NMS was frequently observed among younger
patients, more often neuroleptic-naı¨ve, who mostly devel-
oped full-blown, severe clinical presentations. Notably, the
presentation of RSP-NMS was characterized by marked
EPS, high temperatures, and great elevations of the indexes
of rhabdomyolysis. Among autonomic signs, tachycardia
was more common than diaphoresis (96 vs. 75 %). On
average, most cardinal signs of NMS had already appeared
1–3 days prior to the formal diagnosis of NMS, while the
onset of fever was recorded only 0.7 days earlier. It seems
likely that fever could have been the sign that led clinicians
to perform further laboratory tests, often carried out on the
same day of the diagnosis. One-third of cases of RSP-NMS
also showed other autonomic gastrointestinal symptoms,
such as vomiting, diarrhea, or sialorrhea, which generally
appeared early in its course. Furthermore, 17 % of cases of
RSP-NMS presented with dysphagia; notably, this symp-
tom has also been described as a dose-dependent, revers-
ible side effect of risperidone, closely related to EPS [44].
After the onset of full-blown NMS, signs of
cardiorespiratory dysregulation appeared in most cases. In
anecdotal cases, RSP-NMS was even accompanied by
acute pancreatitis [45] or dermatologic lesions [46]. RSP-
NMS was treated promptly with high doses of antiparkin-
sonian drugs and, despite it being significantly more severe
than other SGA-NMS, it often led to complete recovery.
Overall, the descriptions provided by available clinical
cases are largely compatible with a ‘typical’ presentation
[42, 47].
4.2.4 Aripiprazole
Since last review on this topic [6], five more cases of ARP-
NMS have been published, with similar characteristics to
those that were already available. Although aripiprazole
was given at standard doses, half of the cases of NMS
seemed to be triggered by a relatively fast titration scheme.
Clinical presentation of ARP-NMS was characterized by
the constant presence of rigidity and mental status changes,
the highest rates of nausea and vomiting, and by a lower
frequency of hyperpyrexia, diaphoresis, and tachypnea than
other SGA-NMS. Despite all cases suffering rigidity and
frequent EPS of other types, rhabdomyolysis seemed to be
associated with lower peaks of CK. All the main symptoms
appeared earlier or on the same day of NMS diagnosis,
with the exception of hyperpyrexia (mean 2.2 days later
than the diagnosis). Fever was also less severe than for
other SGA-NMS. The severity and duration of NMS was
lower than for other SGA-NMS, possibly related to the
peculiar pharmacodynamic profile of aripiprazole. In fact
this compound not only exerts partial agonist activity on
the D2 receptor but also on the D3 D4 and 5-HT1A receptors
[10]. A wide proportion of cases with ARP-NMS were
younger in age and were promptly admitted to the ICU,
which might be the reason for the absence of mortality.
Overall, the clinical picture of ARP-NMS might be con-
sidered, at least in part, ‘atypical’ due to a lower incidence
of high fever and diaphoresis.
4.2.5 Clozapine
Since the publication of the review by Trollor and col-
leagues [6], five more reports of CLZ-NMS have been
published. Cases of CLZ-NMS were characterized by rapid
dose increases, limited concurrent use of antidepressants or
mood stabilizers, and high rates of previous treatments with
other antipsychotics. Furthermore, patients suffering CLZ-
NMS had a more frequent clinical history of previous
NMS. Tachycardia, tachypnea, blood pressure lability, and
other autonomic symptoms were very frequent and severe,
possibly related to the high affinity of clozapine for
adrenergic and muscarinic receptors [48]. Fever was often
one of the first symptoms to appear, together with
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autonomic dysfunction, and this clinical picture often made
it necessary to rule out clozapine-related agranulocytosis
[49]. In fact, increases of CK were lower and delayed [50]
and EPS were generally more rare, consistent with the
lower affinity of clozapine for D2 receptors [51]. EPS
appeared at various stages along the course of CLZ-NMS,
often as mild early signs which were followed by tremor
and, only after a mean of 1.2 days from the diagnosis of
NMS, rigidity. Overall, the duration of CLZ-NMS was
longer than other SGA-NMS but was associated with lower
clinical severity. Consistently, cases of CLZ-NMS
received, less frequently, antiparkinsonian agents and
admission to the ICU; high mortality rates could have
derived from possible underestimation of its severity. The
rarity of EPS in the context of CLZ-NMS has been pre-
viously noted [11, 52, 53], and underlines the need for
taking NMS in consideration even when a full-blown
clinical picture is absent. On the other side, some authors
have argued that some of these cases would fall outside the
boundaries of stringent diagnostic classifications, therefore
they should not diagnosed as NMS in the first place [53].
However, there is little doubt that the presentation of CLZ-
NMS can be considered as the most atypical among SGA-
NMS [6, 11].
4.2.6 Amisulpride
Despite several decades of amisulpride use, only seven
cases of amisulpride-induced NMS (AMI-NMS) have been
described [8, 54–59]. Most cases occurred in older males.
Among the cases of AMI-NMS, four occurred following an
increase in the dose of the drug, and one led to the death of
the patient. The clinical picture was characterized by the
constant presence of mental status alterations, frequent
rigidity (83 %), and high levels of CK. Instead, high fever,
other EPS, and other autonomic symptoms were less fre-
quently reported than in other SGA-NMS. Based on these
findings some authors, but not all [11], have advocated for
an ‘atypical’ presentation of AMI-NMS [57, 58]. Further-
more, similar to CLZ-NMS, the duration of symptoms
appeared to be slightly longer than for other SGA-NMS;
this could reflect the fact that patients received less prompt
or intensive clinical management. Considering its phar-
macologic properties, amisulpride has a peculiar mecha-
nism of action that relies on a delayed pattern of D2/D3
receptor occupancy, involving also presynaptic mecha-
nisms with an apparent specificity for mesolimbic path-
ways. These features are thought to be related to its low
capacity to induce EPS, and might also explain the low
occurrence of NMS with this drug [60]. Furthermore,
amisulpride has a low affinity for muscarinic, a-adrenergic,
serotonergic, and histamine receptors, which could explain
the lower induction of autonomic dysfunction [61].
4.2.7 Paliperidone
PAL is the main active metabolite of RSP and has a similar
receptor profile, being a D2 receptor antagonist—although
with lower affinity than RSP- and a 5-HT2A antagonist
[62]. Only four cases of NMS were induced by paliperi-
done [63–66], three of which emerged in patients suffering
from schizophrenia, and appeared when subjects were
treated at doses of 6–9 mg. Most cases had been previously
treated with other SGAs, with recent cross-titration
schemes or dose increases. Paliperidone-induced NMS
(PAL-NMS) was characterized by a typical presentation,
with nearly all cases presenting with mental status alter-
ation, rigidity, diaphoresis, hyperpyrexia (even if only half
of the cases reached a temperature higher than 38 C),
tremor, and other EPS. All cases had a favorable evolution,
with complete recovery of patients.
4.2.8 Ziprasidone
Six cases of ziprasidone-induced NMS (ZPR-NMS) were
included [67–72], whereas a previous review examined five
cases [6]. The mean age of patients was 35 years; two-
thirds of patients were females and the same proportion
was diagnosed with a psychotic disorder. The onset of
NMS was generally abrupt, with most cases displaying
typical symptoms such as alterations of mental status,
diaphoresis, hyperpyrexia, tachycardia, blood pressure
alterations, leukocytosis, tremor, and other EPS. Levels of
CK were very high and became evident soon after the onset
of the syndrome; however, only half of the cases reached a
temperature higher than 38 C. Notably, in two cases
rigidity was absent [67, 72], while in one case it super-
imposed on pre-existing Parkinson’s disease [68]. Hence,
the effective presence of rigidity might be lower for ZPR-
NMS than for other SGA-NMS, consistent with a lower
affinity for D2 receptors [73]. The overall outcome of ZPR-
NMS was generally favorable; no case was lethal and most
patients underwent complete recovery within 10 days of
diagnosis.
4.2.9 Zotepine
Zotepine is an atypical antipsychotic antagonizing seroto-
nin (5-HT2A,5-HT2C, 5-HT6, and 5-HT7) and dopamine (D1
and D2) receptor. Furthermore, it also has noradrenaline
reuptake inhibition properties [74]. Four cases of ZOT-
NMS were found [75–78]. Only one case occurred in a
woman, and the mean age of patients was higher than
among other cases of SGA-NMS (52.5 years). Rapid dose
escalation was reported in only one case prior to zotepine-
induced NMS (ZOT-NMS) onset, but the mean dose was in
the high range (325 mg). ZOT-NMS was characterized by
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most cardinal symptoms and by a slightly longer duration
than other SGA-NMS (15 days). All cases were reported to
present with alterations of mental status, rigidity, diapho-
resis, hyperpyrexia, tachycardia, and leukocytosis. How-
ever, a lower proportion displayed high fever, tremor,
tachypnea, alterations in pressure or other symptoms of
autonomic imbalance. On average, mean CK values
showed a large increase in the days following NMS diag-
nosis (from 2,130 to a peak value of 39,190 UI/l), similar
to what was observed in CLZ-NMS. All cases underwent
complete recovery.
4.3 Diagnostic Issues
Considering the case reports of SGA-NMS that were
reviewed, it is surprising that very few authors stated which
set of diagnostic criteria they relied on. In the past years
more than 12 sets of criteria were proposed to operation-
alize NMS, each characterized by different type, number of
symptoms, and by differences in the weight they are given
to establish the diagnosis [1, 79]. There is still ongoing
debate regarding which clinical features should be used to
diagnose NMS; disagreement between diagnostic criteria
appears to be high, and most criteria sets do not correspond
to the empirical diagnoses that are adopted in clinical
practice [80].
In our review, the DSM-IV-TR criteria were the most
frequently used and could be considered as fairly stringent;
they require the presence of both elevated temperature
(without defining a specific threshold) and severe muscle
rigidity, plus two other minor criteria such as autonomic
disorders, other EPS, mental status changes, and laboratory
alterations [23]. The criteria set by Adityanjee and Ader-
ibigbe are among the most stringent, and require both fever
over 39 C and rigidity as necessary conditions to diagnose
NMS; by admission of the authors themselves, several cases
of SGA-NMS would not reach the diagnostic threshold [79].
On the contrary, Levenson proposed that NMS could be
diagnosed even in the absence of rigidity, if CK alterations
were observed [24]. This would allow an easier inclusion
of atypical forms, although the diagnostic boundaries of
NMS would lose specificity [16, 42]. Similarly, other cri-
teria set allow the possibility of diagnosing probable, as
opposed to definite, cases of NMS by including those cases
without cardinal signs, such as rigidity or fever [26, 81].
Several authors have in fact advocated for the adoption of a
spectrum-conceptualization of NMS (i.e. using a dimen-
sional model rather than a dichotomous approach), which
might help in clarifying the pathogenetic mechanisms of
this syndrome [16]. Indeed, it was argued that the rise of
clinical awareness towards NMS and the more widespread
availability of treatments makes the natural course of the
syndrome more likely to be influenced by early treatments
and/or antipsychotic discontinuation, possibly leading to
frequent observations of prodromal or abortive stages [6,
16, 82]. On a similar note, other authors proposed to add
diagnostic specifiers for the clinical stage of NMS [83, 84].
More recently, a new set of criteria was developed and
validated by a panel of experts using a Delphi consensus
method [1, 85], and was incorporated into the DSM-5 [86].
Interestingly, these criteria do not imply the need for a
specific number of ‘major’ or ‘minor’ symptoms, but pro-
vide specific quantitative criteria for the severity of
symptoms, with a pre-defined threshold score used to
define the ‘caseness’ of NMS. This approach might be
more suitable to inform future research on NMS, taking
into account the existing clinical variants.
4.4 Pathogenesis
NMS can be described as a complex cascade of dysregu-
lation in multiple neurochemical and neuroendocrine sys-
tems, potentially culminating in an end-stage
hypermetabolic syndrome [84]. It has been generally
regarded as an idiosyncratic drug reaction, implying that it
is unpredictable and dose-independent, although this view
has been recently challenged in consideration of cases of
NMS induced by antipsychotic withdrawal [15, 17].
However, individual vulnerability for the development of
NMS might exist, related to variations in the genes for
neurotransmitter receptors or metabolic activity, although
evidence in this regard is still preliminary [87, 88].
The exact pathogenetic mechanism that underlies NMS
is still partly unknown. The fundamental triggering element
seems to be a reduction in CNS dopaminergic tone, along
with the dysregulation of autonomic nervous system
activity, characterized by a loss of hierarchical integration
and control. The functional imbalances seen during NMS
are maintained by different feed-forward cycles that
involve an increasing number of systems, leading to pro-
gressive damage of the muscular tissue and multi-organ
failure [84, 89]. The hypothesis of hypodopaminergic tone
was mainly based on the notion that the risk of developing
NMS seemed to parallel the ability of the antipsychotic to
induce EPS and the degree of inhibition of dopamine
receptor activity, particularly the D2 subtype in the nigro-
striatal pathways [16, 84]. Reductions in the dopaminergic
tone are also deemed responsible for the abrupt shifts that
occur in the activity of the hypothalamic thermoregulatory
system, which would in turn induce further dysregulation
of the autonomic response [4, 84]. However, the report of
NMS induced by withdrawal of antipsychotic [15] or
induced by the use of SGAs such as clozapine, aripiprazole
and amisulpride have cast doubt on the primary role of D2
receptors, at least on the notion that D2 receptors play a
predominant role in all cases of NMS [16, 53, 89]. In fact,
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these SGAs possess only weak activity at this level, with
aripiprazole even acting as a partial agonist [10]. Not
coincidentally, our case review showed that the same SGAs
are associated with the highest rates of NMS with atypical
features, i.e. lacking severe EPS/rigidity, high fever, or
grossly elevated CK. Thus, it is now widely acknowledged,
although awaiting further confirmation, that receptors other
than dopaminergic (i.e. serotonergic, adrenergic, and cho-
linergic) might play an important role in the pathophysi-
ology of NMS since they are known to take substantial part
in extrapyramidal motor functions [90], thermoregulation,
muscle metabolism [89], and mental status [16].
The serotonergic receptors, in particular, have gained
increasing attention in recent years as possible contributors
to the pathophysiology of NMS, especially that induced by
SGAs. In part, this hypotheses spawned from the obser-
vation that important similarities exist between NMS and
serotonin syndrome at the clinical level. According to this
line of research, serotonin-related toxicity would be
responsible for the pathogenesis of at least some symptoms
of NMS, and this would be particularly evident among
atypical SGA-NMS [91–93]. In apparent contrast with this
hypothesis, most SGAs antagonize 5-HT2A receptors, and
were even suggested for use in the treatment of serotonin
syndrome. However, it is noteworthy that quetiapine, ari-
piprazole, clozapine, and ziprasidone share agonistic
actions at 5-HT1A receptors; their stimulation was thus
proposed to contribute to lower degrees of hyperthermia or
EPS that are observed in some cases of SGA-NMS [16,
90]. Moreover, it was recently hypothesized that long-term
treatment with SGAs might determine unbalances in
serotonergic neurotransmission, leading to sensitization
towards SGAs and other psychotropic agents [94, 95].
Lastly, the observation of cases of NMS apparently pre-
cipitated by antidepressants, lithium, or other mood stabi-
lizers have further highlighted a possible pathogenetic role
for serotonin, although these drugs are unlikely to trigger
NMS alone, in the absence of previous antipsychotic use.
However, it was postulated that an excess of central sero-
tonin due to antidepressant use could determine a ‘relative
hypodopaminergic state’, which might increase the risk of
developing NMS [96, 97]. In our case review, only statis-
tical trends were found for an association between antide-
pressants and worse clinical picture of NMS, and further
studies based on larger samples are warranted before any
clear role of these drugs can be confirmed. Overall, further
evidence is also needed to elucidate the role of serotonergic
neurotransmission in the pathophysiology of NMS.
4.5 Limitations
Our review needs to be evaluated in the light of its limi-
tations, particularly related to the case review.
A dataset based on published case reports is only par-
tially representative of the clinical reality because of its
intrinsic nature. It can be affected by reporting biases
related both to the reporting clinicians (e.g. authors might
have tended to more frequently report cases of NMS with
more peculiar presentations; some symptoms could be
omitted from the report because they were not considered
to depend on NMS, and in some cases serotonin syndrome
might have been misdiagnosed for NMS) and to peer
reviewers (e.g. possible lower acceptance rates for cases of
SGA-NMS for which a wider literature already exists).
However, since SGA-NMS is a rare condition, case reports
are, by necessity, one of the few available sources of
information.
We also included those cases where the authors did not
report validating the diagnosis against standardized crite-
ria; it is possible that if such criteria were applied, some
cases would not have reached a formal diagnosis of NMS,
possibly because patients received early treatment and
underwent a partial resolution of symptoms [15]. Hence,
the interpretation of findings needs to take into account a
possible overrepresentation of atypical cases. However, it
needs to be considered that, even when standardized cri-
teria for NMS are used, agreement between different sets is
still limited [15, 80], while the process of peer review of
reports might contribute to filter out the more ambiguous
cases [6]. Lastly, this inclusive approach is in line with the
conceptualization of NMS as a spectrum proposed by
several authors [16, 80].
The method for the extraction and coding of data was
designed to be as conservative as possible, e.g. abstaining
from labeling as absent those symptoms that were not
mentioned in the reports. Nonetheless, this method might
have introduced bias in the frequency of some symptoms,
particularly towards overestimation. However, data on
missing values were provided to aid in the interpretation of
results.
Given the subgroup size, the statistical power was
inadequate to detect some meaningful differences; there-
fore, statistical analyses should be considered only as
exploratory and hypothesis generating.
5 Conclusions and Directions for Future Research
Clinicians should be aware that NMS is virtually associated
with all antipsychotics, including the most recently mar-
keted antipsychotics. SGA-NMS seems characterized by
lower incidence, lower clinical severity, and more rare
lethal outcomes than FGA-NMS. The clinical presentation
of NMS induced by olanzapine, risperidone, quetiapine,
paliperidone, and ziprasidone seems to be widely similar to
that of ‘typical’ NMS, whereas ‘atypical’ presentations
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might be observed more frequently during NMS triggered
by clozapine (less severe EPS), aripiprazole (less severe
fever and autonomic symptoms), and amisulpride (less
severe EPS and fever). The clinician should pay particular
attention to cases developing in older individuals and those
receiving antidepressant drugs as these factors might
increase the risk of mortality.
Further research is greatly needed to increase our
knowledge on NMS and its pathophysiology in order to
inform the clinical management of this severe condition. In
particular, since case reports or pharmacovigilance systems
are the main current sources of information, it would be
desirable to develop standardized and systematic reporting
methods to include detailed, relevant information on the
course and severity of symptoms. Research would also
likely benefit from the adoption of a spectrum conceptu-
alization of NMS, with heightened vigilance on symptoms
of autonomic dysregulation and serotonin toxicity. More-
over, further studies are needed to understand the role of
individual liability for NMS (both genetic and related to
individual features, such as physical comorbidities), the
role of concomitant use of antidepressants, and other psy-
chotropic medication. The recent development of novel,
validated diagnostic criteria seems a promising step in this
direction [1].
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